Funded Biotechnology Startups in Vancouver
The largest disclosed round in this Vancouver-focused biotechnology set is NervGen Pharma’s $60M on 2026-05-21; the next-largest disclosed amounts are $183…
The largest disclosed round in this Vancouver-focused biotechnology set is NervGen Pharma’s $60M on 2026-05-21; the next-largest disclosed amounts are $183M (Zymeworks, 2026-03-02) and $175M (Alpha9 Theranostics, 2024-10-23), meaning the $60M round is not the top of the table, but it still sits well above the many sub-$5M entries. Several amounts cluster around major financing dates: there are multiple 2026 rounds in May (e.g., NervGen Pharma $60M on 2026-05-21; Anodyne Chemistries $720K on 2026-05-26; Zymeworks $183M is earlier in March on 2026-03-02) rather than a uniform spread.
Geographically, the list is overwhelmingly Vancouver, British Columbia, though it includes out-of-province/out-of-metro entries such as Cytodyn (Vancouver, Washington, 2026-03-05, $18M) and Geno10X Biosciences (Vancouver, Alberta, 2025-03-06, undisclosed). Stage information is frequently non-specified: “Series Unknown” appears in 28 of 36 rows, while undisclosed appears once (Geno10X Biosciences, 2025-03-06). Temporally, disclosed rounds span 2020-05-27 (AbCellera Biologics) through 2026-06-03 (ME Therapeutics), with many entries concentrated in 2022–2026.
Most recent rounds
36 shownRelated listings
Frequently asked
Which disclosed rounds are the true outliers in size, and how far above the rest are they?
Alpha9 Theranostics’ $175M (2024-10-23) and Zymeworks’ $183M (2026-03-02) dwarf the rest of the disclosed amounts; after those, the next-largest entries include Lungpacer Medical $12M (2026-04-28) and enGene $18M (2026-01-20). The smallest disclosed amount is $30K for Tait Labs on 2023-10-24, making it far below the dominant $M-scale rounds.
Are there any tight date windows where funding is unusually concentrated?
The 2026 entries show a clear late-spring cluster: May 2026 includes ME Therapeutics $360K (2026-06-03 is close), Anodyne Chemistries $720K (2026-05-26), and NervGen Pharma $60M (2026-05-21), with additional 2026 financings in April (e.g., Lungpacer Medical $12M on 2026-04-28). Earlier, 2024 also clusters with large rounds in October (Alpha9 Theranostics $175M on 2024-10-23) alongside other 2024 activity.
Does the geography skew heavily toward a single city name, or are there meaningful location exceptions?
Most companies are listed in Vancouver, British Columbia (e.g., Zymeworks 2026-03-02 for $183M; Ondine Biomedical 2024-11-01 for $12M). Exceptions include Cytodyn in Vancouver, Washington ($18M on 2026-03-05) and Geno10X Biosciences in Vancouver, Alberta (2025-03-06, undisclosed), so the city name repeats but the jurisdiction does not.
What stage mix dominates, and how often is stage not provided?
“Series Unknown” appears 28 of 36 rows, so any stage-based conclusions need caution. Where stages are specified, notable examples include Virogin Biotech’s Series D $120M (2021-09-24) and SaNOtize’s Series B $24M (2022-08-24), but they are minority compared with the “Series Unknown” entries.
Which entries are in the most recent 90 days of the table, and do they show a consistent size pattern?
Using the latest row date of 2026-06-03 (ME Therapeutics), the most recent 90-day window includes entries from roughly early March 2026 onward: Zymeworks $183M (2026-03-02), NervGen Pharma $60M (2026-05-21), Anodyne Chemistries $720K (2026-05-26), and ME Therapeutics $360K (2026-06-03). Sizes vary widely in that window, from sub-$1M rounds (e.g., Restart Life Science $70K on 2026-05-08) to $60M+ rounds (NervGen Pharma).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.